228 related articles for article (PubMed ID: 29290332)
1. Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
Guo J; Wu M; Guo L; Zuo Q
Bull Cancer; 2018 Feb; 105(2):146-154. PubMed ID: 29290332
[TBL] [Abstract][Full Text] [Related]
2. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgically Resectable Pancreatic Neuroendocrine Tumors.
Zhou B; Zhan C; Wu J; Liu J; Zhou J; Zheng S
Med Sci Monit; 2017 Nov; 23():5574-5588. PubMed ID: 29168979
[TBL] [Abstract][Full Text] [Related]
5. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
Qi Q; Geng Y; Sun M; Wang P; Chen Z
Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
10. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
11. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer.
Aliustaoglu M; Bilici A; Seker M; Dane F; Gocun M; Konya V; Ustaalioglu BB; Gumus M
Hepatogastroenterology; 2010; 57(99-100):640-5. PubMed ID: 20698242
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
Cetin S; Dede I
J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
[TBL] [Abstract][Full Text] [Related]
13. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
[TBL] [Abstract][Full Text] [Related]
14. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
15. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
[TBL] [Abstract][Full Text] [Related]
16. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
17. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.
Cheng H; Luo G; Lu Y; Jin K; Guo M; Xu J; Long J; Liu L; Yu X; Liu C
Pancreatology; 2016; 16(6):1080-1084. PubMed ID: 27665172
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis.
Yang JJ; Hu ZG; Shi WX; Deng T; He SQ; Yuan SG
World J Gastroenterol; 2015 Mar; 21(9):2807-15. PubMed ID: 25759553
[TBL] [Abstract][Full Text] [Related]
19. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
[TBL] [Abstract][Full Text] [Related]
20. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
